GSK PLC Sponsored ADR $GSK Stock Bought by Vise Technologies Inc.

Vise Technologies Inc. lifted its holdings in shares of GSK PLC Sponsored ADR (NYSE:GSK) by 17.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 162,248 shares of the pharmaceutical company’s stock after acquiring an additional 24,123 shares during the quarter. Vise Technologies Inc.’s holdings in GSK were worth $7,815,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Summit Global Investments increased its holdings in shares of GSK by 123.5% in the third quarter. Summit Global Investments now owns 46,599 shares of the pharmaceutical company’s stock valued at $2,245,000 after purchasing an additional 25,747 shares during the last quarter. Aprio Wealth Management LLC lifted its stake in shares of GSK by 19.2% during the 3rd quarter. Aprio Wealth Management LLC now owns 9,318 shares of the pharmaceutical company’s stock worth $449,000 after buying an additional 1,504 shares during the last quarter. Soltis Investment Advisors LLC acquired a new stake in shares of GSK during the 3rd quarter worth about $246,000. Founders Financial Securities LLC lifted its stake in shares of GSK by 1.0% during the 3rd quarter. Founders Financial Securities LLC now owns 21,884 shares of the pharmaceutical company’s stock worth $1,054,000 after buying an additional 211 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of GSK during the 3rd quarter worth about $494,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Down 0.8%

GSK opened at $49.11 on Tuesday. The stock has a fifty day moving average of $49.37 and a 200-day moving average of $52.34. The company has a market capitalization of $99.34 billion, a P/E ratio of 10.26, a P/E/G ratio of 2.12 and a beta of 0.33. GSK PLC Sponsored ADR has a fifty-two week low of $45.81 and a fifty-two week high of $61.69. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be given a dividend of $0.4518 per share. This is a positive change from GSK’s previous quarterly dividend of $0.4515. This represents a $1.81 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date of this dividend is Friday, November 13th. GSK’s payout ratio is 61.46%.

Wall Street Analyst Weigh In

GSK has been the topic of several research analyst reports. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and lowered their price target for the company from $67.40 to $55.90 in a report on Thursday, October 29th. Barclays restated a “sell” rating on shares of GSK in a report on Monday, September 7th. Wolfe Research started coverage on GSK in a report on Friday, October 9th. They set an “outperform” rating and a $70.00 price objective for the company. Sanford C. Bernstein reaffirmed a “buy” rating on shares of GSK in a research report on Sunday, August 2nd. Finally, JPMorgan Chase & Co. reiterated a “sell” rating on shares of GSK in a research note on Thursday, October 1st. Three research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $56.30.

GSK Profile

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.